Neurosterix Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 29

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $105M

  • Investors
  • 9

Neurosterix General Information

Description

Developer of allosteric modulator therapies designed to treat neuropsychiatric disorders. The company offers a proprietary drug discovery platform that identifies modulators targeting receptors outside the active site, enabling the development of schizophrenia therapies, mood disorder treatments, cognition therapies, central nervous system modulators and ind enabling studies, providing healthcare providers with precision medicines for complex brain health conditions.

Contact Information

Website
www.neurosterix.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 9 Chemin Des Mines
  • 1202 Geneva
  • Switzerland
+41 022
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 9 Chemin Des Mines
  • 1202 Geneva
  • Switzerland
+41 022

Neurosterix Timeline

20252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurosterix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 11-Nov-2026 $105M Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 02-Apr-2024 Completed Clinical Trials - Phase 1
1. Spin-Off 12-Mar-2024 Completed Startup
To view Neurosterix’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Neurosterix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of allosteric modulator therapies designed to treat neuropsychiatric disorders. The company offers a proprieta
Drug Discovery
Geneva, Switzerland
29 As of 2026

Framingham, MA
 

Eysins, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurosterix Competitors (77)

One of Neurosterix’s 77 competitors is Alzheon, a Venture Capital-Backed company based in Framingham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alzheon Venture Capital-Backed Framingham, MA
Asceneuron Venture Capital-Backed Eysins, Switzerland
Cerecin Venture Capital-Backed Broomfield, CO
ZyVersa Therapeutics Formerly VC-backed Lighthouse Point, FL
NeuroDerm Formerly VC-backed Rehovot, Israel
You’re viewing 5 of 77 competitors. Get the full list »

Neurosterix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurosterix Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Affinity Asset Advisors Hedge Fund Minority
Dellora Investments Hedge Fund Minority
GV Corporate Venture Capital Minority
Ikarian Capital Hedge Fund Minority
Janus Henderson Investors Asset Manager Minority
You’re viewing 5 of 9 investors. Get the full list »

Neurosterix Investments (1)

Neurosterix’s most recent deal was a Corporate Asset Purchase with Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform). The deal was made on 02-Apr-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Addex Therapeutics (Portfolio of Preclinical Assets and Drug Discovery Platform) 02-Apr-2024 Corporate Asset Purchase Buildings and Property
To view Neurosterix’s complete investments history, request access »

Ready to get started?

Request a free trial

Neurosterix FAQs

  • When was Neurosterix founded?

    Neurosterix was founded in 2024.

  • Where is Neurosterix headquartered?

    Neurosterix is headquartered in Geneva, Switzerland.

  • What is the size of Neurosterix?

    Neurosterix has 29 total employees.

  • What industry is Neurosterix in?

    Neurosterix’s primary industry is Drug Discovery.

  • Is Neurosterix a private or public company?

    Neurosterix is a Private company.

  • What is Neurosterix’s current revenue?

    The current revenue for Neurosterix is .

  • How much funding has Neurosterix raised over time?

    Neurosterix has raised $170M.

  • Who are Neurosterix’s investors?

    Affinity Asset Advisors, Dellora Investments, GV, Ikarian Capital, and Janus Henderson Investors are 5 of 9 investors who have invested in Neurosterix.

  • Who are Neurosterix’s competitors?

    Alzheon, Asceneuron, Cerecin, ZyVersa Therapeutics, and NeuroDerm are some of the 77 competitors of Neurosterix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process